Author: sHq_LoGiNz

ROCHESTER, Minn., June 10, 2026 /3BL/ – Urbaneer and the Well Living Lab recently hosted a networking event showcasing plans for the Home Innovation Lab (HIL), an innovative residential home designed to demonstrate how research, technology, and human-centered design can support healthier living environments and aging in place. The site will include a residential research environment focused on human-centered living as well as an experience center designed to evaluate emerging products and technologies in a real-world home setting.

Held at the Well Living Lab in downtown Rochester, Minnesota, in the heart of the Destination Medical Center (DMC) district, the event was planned in conjunction with DMC’s annual Real Estate & Investment Summit and welcomed developers, builders, healthcare leaders, researchers, and community stakeholders for conversations centered on the future of residential wellness and housing innovation.

Attendees explored the Home Innovation Lab renderings, educational displays, research insights, and interactive experiences highlighting how residential environments can better support health and well-being through evidence-based design. Key focus areas included indoor air quality, lighting, sleep, stress recovery, biophilic design, and technology-enabled solutions that support aging in place and long-term wellness.

“The Home Innovation Lab reflects the kind of forward-thinking collaboration that continues to position Rochester as a leader in innovation and as America’s City for Health,” said Patrick Seeb, Executive Director, DMC EDA. “As communities nationwide navigate evolving housing needs and demographic shifts, initiatives like this demonstrate how technology and cross-industry partnerships can help shape healthier homes and more resilient communities.”

“We are seeing a major shift in the market, with consumer demand rising fast for healthy homes, which we know can play a critical role supporting human health and well-being,” said Rachel Hodgdon, President and CEO, International WELL Building Institute. “Initiatives like the Home Innovation Lab — alongside the growing momentum behind WELL for residential — demonstrate how research, technology and thoughtful residential design can come together to support healthier living environments for people across every stage of life.”

Construction on the Home Innovation Lab is anticipated to begin in the fourth quarter of 2026, with the Lab expected to be fully operational by the second quarter of 2027.

# # #

About Urbaneer

Urbaneer is a wellness real estate and residential intelligence company focused on creating healthier, technology-enabled living environments that support comfort, safety, and well-being across all stages of life. With more than a decade of specialized expertise, Urbaneer has completed more than 30 residential projects across five states and continues to advance technology-driven approaches that support health and healthcare delivery within the home. For more information, visit urbaneerliving.com or contact Bruce Thompson, CEO, at bruce@urbaneerliving.com.

About the Well Living Lab

The Well Living Lab, founded in 2016 as a collaboration between Delos and Mayo Clinic, is the first research facility dedicated exclusively to studying the real-world impact of indoor environments on human health and well-being. To date, the Well Living Lab has completed 43 studies and generated 45 peer-reviewed publications, with formal academic affiliations including the University of Minnesota. For more information, visit welllivinglab.com or contact Barb Spurrier, Executive Director, at barbara.spurrier@delos.com.

Contact: Sarah Kelling, Director of Communications & Marketing, Well Living Lab

507.421.9864 | sarah.kelling@delos.com

Originally published on CVS Health Company Newsroom

WOONSOCKET, R.I., June 10, 2026 /3BL/ – CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members— including the reintroduction of Zepbound® (tirzepatide) as a covered medication. These changes build on Caremark’s industry leading efforts as a pharmacy benefits manager to explore all potential avenues that help patients get FDA-approved weight management medications at an affordable cost. Plan sponsors that adopt CVS Caremark template formularies retain discretion to customize coverage for their members.

What changes is CVS Caremark making to its weight management drug coverage?

CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members. Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo™(orforglipron), a new oral GLP-1 therapy, where approved for coverage by plans.

Over the past year, we’ve been actively driving change in the GLP-1 weight management space to help lower costs. Our approach has made a real difference, enabling us to now expand options while continuing to make progress on affordability.

We expect these changes to help drive increased savings in the weight management category – after a history of delivering double digit savings for our template formulary customers year over year – while expanding choice for our members.

Why is CVS Caremark adding Zepbound to their formulary?

Simply put, we achieved what our customers asked us for: deliver affordability and optionality in this important class.

“We’re creating access and options that would not have existed without our leadership in the market,” said Ed DeVaney, President, CVS Caremark. “We acted boldly through active engagement and negotiation with our drug manufacturer partners to tackle affordability and access for our customers and their members.”

What is CVS Caremark doing to bring down the cost of GLP-1s?

Over the past two years, high prices have put these therapies out of reach for the many people who could benefit from them. Last year, we took the initiative to drive engagement with manufacturers to bend the cost curve — similar to how we’ve helped improve affordability for drugs used for diabetes, high cholesterol, psoriasis, rheumatoid arthritis and many more. 

By acting early, we helped improve affordability and get ahead of a rapidly evolving GLP-1 pipeline. This past year, as this therapy class has continued to evolve, we worked with the manufacturers to secure a more affordable cost with positive results that allow us the flexibility to continue offering our customers more choice and access for their members.

What are the challenges with GLP-1 pricing?

While GLP-1s represent a major clinical advancement, the broad demand for a high-priced medicine creates a level of financial strain that is difficult to absorb at scale. As a result, many of our customers have made tough trade-offs, limiting coverage in order to maintain sustainable, balanced benefit programs. Ongoing collaboration with pharmaceutical companies is helping to make this in-demand drug class more accessible.

How was CVS Caremark able to lower the price of these weight management drugs?

As a pharmacy benefit manager, CVS Caremark is hired by businesses, big and small, health plans, unions, and government entities to negotiate the cost of medications included on formularies elected by plan sponsors that offer a benefit to their members. These negotiations have led us to deliver increased affordability and increased access to GLP-1s across the class.

What is a formulary and how does it impact patients?

A formulary is a list of prescription medications available under a health plan, managed with the support of a pharmacy benefit manager. CVS Caremark regularly evaluates formularies — which plan sponsors may adopt or customize based on the needs of their populations — to help support member access to clinically appropriate treatments as evaluated by an independent Pharmacy & Therapeutics committee while helping manage overall medication costs for customers and the members they serve. 

How is CVS Caremark supporting customers and members through these changes?

CVS Caremark will provide advanced communication and/or support to customers, consultants, providers and members to help ensure a smooth transition to covered therapies. These efforts include proactive outreach, educational resources, and clinical support programs. 

These formulary updates are one component of CVS Health’s ongoing efforts to address rising prescription drug costs and improve access to affordable medications for the millions of Americans it serves. 

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, statements regarding the anticipated impact of the formulary changes on affordability, access, and member out-of-pocket costs, as well as statements regarding ongoing engagement with pharmaceutical manufacturers. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in CVS Health’s filings with the Securities and Exchange Commission, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and Current Reports on Form 8-K. You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health does not assume any duty to update or revise forward-looking statements except as required by law.

Media Contact:

Phil Blando
Phillip.Blando@cvshealth.com

Originally published on CVS Health Company Newsroom

WOONSOCKET, R.I., June 10, 2026 /3BL/ – CVS Health (NYSE: CVS) today announced updates to its most common commercial formularies, expanding GLP-1 options for members— including the reintroduction of Zepbound® (tirzepatide) as a covered medication. These changes build on Caremark’s industry leading efforts as a pharmacy benefits manager to explore all potential avenues that help patients get FDA-approved weight management medications at an affordable cost. Plan sponsors that adopt CVS Caremark template formularies retain discretion to customize coverage for their members.

What changes is CVS Caremark making to its weight management drug coverage?

CVS Caremark will add Zepbound back to our commercial formularies as an additional preferred option October 1, 2026, increasing access to GLP-1s at a more affordable price for plan sponsors who elect to provide coverage of those medications for their members. Additionally, effective June 1, 2026, CVS Caremark will remove the new-to-market block on Foundayo™(orforglipron), a new oral GLP-1 therapy, where approved for coverage by plans.

Over the past year, we’ve been actively driving change in the GLP-1 weight management space to help lower costs. Our approach has made a real difference, enabling us to now expand options while continuing to make progress on affordability.

We expect these changes to help drive increased savings in the weight management category – after a history of delivering double digit savings for our template formulary customers year over year – while expanding choice for our members.

Why is CVS Caremark adding Zepbound to their formulary?

Simply put, we achieved what our customers asked us for: deliver affordability and optionality in this important class.

“We’re creating access and options that would not have existed without our leadership in the market,” said Ed DeVaney, President, CVS Caremark. “We acted boldly through active engagement and negotiation with our drug manufacturer partners to tackle affordability and access for our customers and their members.”

What is CVS Caremark doing to bring down the cost of GLP-1s?

Over the past two years, high prices have put these therapies out of reach for the many people who could benefit from them. Last year, we took the initiative to drive engagement with manufacturers to bend the cost curve — similar to how we’ve helped improve affordability for drugs used for diabetes, high cholesterol, psoriasis, rheumatoid arthritis and many more. 

By acting early, we helped improve affordability and get ahead of a rapidly evolving GLP-1 pipeline. This past year, as this therapy class has continued to evolve, we worked with the manufacturers to secure a more affordable cost with positive results that allow us the flexibility to continue offering our customers more choice and access for their members.

What are the challenges with GLP-1 pricing?

While GLP-1s represent a major clinical advancement, the broad demand for a high-priced medicine creates a level of financial strain that is difficult to absorb at scale. As a result, many of our customers have made tough trade-offs, limiting coverage in order to maintain sustainable, balanced benefit programs. Ongoing collaboration with pharmaceutical companies is helping to make this in-demand drug class more accessible.

How was CVS Caremark able to lower the price of these weight management drugs?

As a pharmacy benefit manager, CVS Caremark is hired by businesses, big and small, health plans, unions, and government entities to negotiate the cost of medications included on formularies elected by plan sponsors that offer a benefit to their members. These negotiations have led us to deliver increased affordability and increased access to GLP-1s across the class.

What is a formulary and how does it impact patients?

A formulary is a list of prescription medications available under a health plan, managed with the support of a pharmacy benefit manager. CVS Caremark regularly evaluates formularies — which plan sponsors may adopt or customize based on the needs of their populations — to help support member access to clinically appropriate treatments as evaluated by an independent Pharmacy & Therapeutics committee while helping manage overall medication costs for customers and the members they serve. 

How is CVS Caremark supporting customers and members through these changes?

CVS Caremark will provide advanced communication and/or support to customers, consultants, providers and members to help ensure a smooth transition to covered therapies. These efforts include proactive outreach, educational resources, and clinical support programs. 

These formulary updates are one component of CVS Health’s ongoing efforts to address rising prescription drug costs and improve access to affordable medications for the millions of Americans it serves. 

About CVS Health

CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company’s integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Cautionary Statement Concerning Forward-Looking Statements

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by or on behalf of CVS Health Corporation. Statements in this press release that are forward-looking include, but are not limited to, statements regarding the anticipated impact of the formulary changes on affordability, access, and member out-of-pocket costs, as well as statements regarding ongoing engagement with pharmaceutical manufacturers. By their nature, all forward-looking statements are not guarantees of future performance or results and are subject to risks and uncertainties that are difficult to predict and/or quantify. Actual results may differ materially from those contemplated by the forward-looking statements due to the risks and uncertainties described in CVS Health’s filings with the Securities and Exchange Commission, including those set forth in the Risk Factors section and under the heading “Cautionary Statement Concerning Forward-Looking Statements” in our most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and Current Reports on Form 8-K. You are cautioned not to place undue reliance on CVS Health’s forward-looking statements. CVS Health does not assume any duty to update or revise forward-looking statements except as required by law.

Media Contact:

Phil Blando
Phillip.Blando@cvshealth.com